In a study, patients who experienced hyperkalemia while on a renin-angiotensin-aldosterone-system inhibitor had the lowest 1-year risk of recurrent hyperkalemia when the medication was discontinued.
Trends suggest that clinical practice could be driven heavily by providers’ preferences and beliefs, resulting in substantial practice variation.
Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.
The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.
The sNDA is supported by data from the phase 3 EMPEROR-Reduced trial which compared the efficacy and safety of empagliflozin to placebo, in addition to recommended therapy, in 3730 patients with chronic heart failure with reduced ejection fraction.
The FDA has granted Priority Review to dapagliflozin (Farxiga) for the treatment of new or worsening CKD.
The Agency announced that additional clarification of clinical data was needed prior to completing the review.
The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.
The designation was granted based on results from the phase 3 DAPA-CKD trial, which was stopped early due to “overwhelming efficacy”.
Tenapanor is a first-in-class oral medication that works by blocking the NHE3 transporter in the gastrointestinal tract.
